Amplifyer Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amplifyer Bio, Inc. - overview
Established
2023
Location
Lexington, MA, US
Primary Industry
Biotechnology
About
Based in the US, and founded in 2023 by Eric Huang, Amplifyer Bio, founded through collaboration between Sangeeta Bhatia, Chris Love, and Viktor Adalsteinsson, associated with MIT and the Broad Institute, provides biotechnology services. In September 2024, Amplifyer Bio, Inc. raised USD 7. 08 million in seed funding from various investors.
Amplifyer Bio's focus is on creating novel priming agents designed to enhance the performance of existing liquid biopsy diagnostics. Its initial program targets the enhancement of circulating free DNA (cfDNA) levels in blood, with a primary application in cancer diagnostics. This approach aims to provide physicians and patients with higher-quality genomic data to support improved clinical decision-making and outcomes.
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Oncology/Cancer Treatment
Website
www.amplifyer.bio/
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.